NVS:NYSENovartis AG Analysis

Novartis (NVS) is trading at $152.01, just below the calculated resistance of $152.55 and comfortably above its 20‑day ($147.59) and 50‑day ($149.70) moving averages, indicating short‑term bullish momentum. The MACD histogram is positive (0.81) and the signal line is bearish, producing a bullish MACD signal, while the RSI sits at 57.7, suggesting the stock is not yet overbought. However, volume is on a decreasing trend and the Fear & Greed Index reads 91.25 (Extreme Greed), flagging heightened market optimism that could cap upside. On the fundamentals side, the company delivers strong profitability with a 30.5% operating margin and a 23.9% net profit margin, and its ROE of 34.9% far exceeds industry norms. Revenue is flat to slightly negative (‑0.7% YoY), but the forward P/E of 15.3 is well below the industry average of 27.6, indicating relative valuation attractiveness. The balance sheet is leveraged, with a debt‑to‑equity ratio of 120.7, yet operating cash flow ($19.2B) and free cash flow ($12.0B) remain robust. Dividend yield stands at 3.12% with a payout ratio of 68%, supporting the case for income stability. A DCF model suggests a fair value near $61, implying the market price is substantially above intrinsic estimates, though analysts’ median target of $151.6 points to modest upside. Recent news of a new radioligand therapy manufacturing facility in Texas underscores ongoing pipeline investment. Overall, the stock appears fairly priced with a blend of growth and value attributes, but high leverage and near‑term technical resistance temper enthusiasm.